Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology announced equity grants to four new employees as inducement awards under Nasdaq Rule 5635(c)(4). The grants include 26,300 stock options and 13,200 restricted stock units. The stock options were granted at $4.18 per share, matching Nasdaq's closing price on December 2, 2024.
The options have a ten-year term with a four-year vesting schedule: 25% vests after one year, followed by quarterly vesting of 6.25%. The restricted stock units vest over four years at 25% annually. Both grants are subject to continued employment and the company's 2024 Inducement Stock Option and Incentive Plan.
Mural Oncology ha annunciato concessioni azionarie a quattro nuovi dipendenti come premi di inducimento ai sensi della Regola 5635(c)(4) di Nasdaq. Le concessioni includono 26.300 opzioni azionarie e 13.200 unità azionarie vincolate. Le opzioni azionarie sono state concesse a $4,18 per azione, corrispondente al prezzo di chiusura di Nasdaq del 2 dicembre 2024.
Le opzioni hanno un termine di dieci anni con un programma di maturazione di quattro anni: il 25% matura dopo un anno, seguito da una maturazione trimestrale del 6,25%. Le unità azionarie vincolate maturano in quattro anni al 25% annually. Entrambe le concessioni sono soggette a permanenza nel lavoro e al Piano di Opzioni Azionarie di Inducimento e Incentivi 2024 della società.
Mural Oncology anunció concesiones de acciones a cuatro nuevos empleados como premios de inducimiento bajo la Regla 5635(c)(4) de Nasdaq. Las concesiones incluyen 26,300 opciones sobre acciones y 13,200 unidades de acciones restringidas. Las opciones sobre acciones se otorgaron a $4.18 por acción, coincidiendo con el precio de cierre de Nasdaq del 2 de diciembre de 2024.
Las opciones tienen un plazo de diez años con un cronograma de adquisición de cuatro años: el 25% se adquiere después de un año, seguido de una adquisición trimestral del 6.25%. Las unidades de acciones restringidas se adquieren en cuatro años al 25% anualmente. Ambas concesiones están sujetas a la continuidad del empleo y al Plan de Opciones de Acciones de Inducimiento e Incentivos 2024 de la empresa.
Mural Oncology는 Nasdaq 규정 5635(c)(4)에 따라 유인 보상으로 네 명의 새 직원에게 주식 보상을 발표했습니다. 이 보상에는 26,300개의 주식 옵션과 13,200개의 제한 주식 단위가 포함됩니다. 주식 옵션은 2024년 12월 2일 나스닥 종가인 주당 $4.18에 부여되었습니다.
옵션의 유효 기간은 10년이며, 4년의 베스팅 일정이 있습니다. 첫 해에 25%가 베스팅되고, 이후에는 분기마다 6.25%가 베스팅됩니다. 제한 주식 단위는 4년 동안 매년 25%씩 베스팅됩니다. 두 보상 모두 계속 근무하는 것과 회사의 2024년 유인 주식 옵션 및 인센티브 계획에 따라 달라집니다.
Mural Oncology a annoncé des concessions d'équité à quatre nouveaux employés sous forme de récompenses d'incitation conformément à la règle 5635(c)(4) de Nasdaq. Les concessions comprennent 26 300 options d'achat d'actions et 13 200 unités d'actions restreintes. Les options d'achat d'actions ont été accordées à 4,18 $ par action, correspondant au prix de clôture de Nasdaq du 2 décembre 2024.
Les options ont un terme de dix ans avec un calendrier d'acquisition de quatre ans : 25 % sont acquises après un an, suivies d'une acquisition trimestrielle de 6,25 %. Les unités d'actions restreintes s'acquièrent sur quatre ans à raison de 25 % par an. Les deux concessions sont soumises à la continuité de l'emploi et au plan d'options d'achat d'actions et d'incitation de 2024 de la société.
Mural Oncology hat vier neuen Mitarbeitern Aktienvergünstigungen als Anreizpreise gemäß der Nasdaq-Regel 5635(c)(4) angekündigt. Die Vergaben umfassen 26.300 Aktienoptionen und 13.200 eingeschränkte Aktieneinheiten. Die Aktienoptionen wurden zu einem Preis von 4,18 $ pro Aktie gewährt, was dem Schlusskurs der Nasdaq am 2. Dezember 2024 entspricht.
Die Optionen haben eine Laufzeit von zehn Jahren mit einem vierjährigen Vesting-Zeitplan: 25 % vesten nach einem Jahr, gefolgt von vierteljährlichem Vesting von 6,25 %. Die eingeschränkten Aktieneinheiten vesten über vier Jahre hinweg zu jeweils 25 % jährlich. Beide Vergaben sind an die fortgesetzte Beschäftigung und den Aktienoptions- und Anreizplan 2024 des Unternehmens gebunden.
- None.
- None.
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on December 2, the Company granted to four newly hired employees (i) non-statutory stock options to purchase an aggregate of 26,300 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 13,200 ordinary shares of the Company, pursuant to the Company’s 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.
Contact
Katie Sullivan
katie.sullivan@muraloncology.com
FAQ
What stock options did Mural Oncology (MURA) grant to new employees in December 2024?
What is the vesting schedule for Mural Oncology's (MURA) December 2024 stock options?
What was the exercise price for Mural Oncology's (MURA) December 2024 inducement stock options?
